Evidence map›Paper›PMID 30197082›Full record

ArticleCell2018

Extracellular Matrix Remodeling Regulates Glucose Metabolism through TXNIP Destabilization.

William J Sullivan, Peter J Mullen, Ernst W Schmid, Aimee Flores, Milica Momcilovic, Mark S Sharpley, David Jelinek, Andrew E Whiteley, Matthew B Maxwell, Blake R Wilde and 8 more

Open access · bronzeAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Cell, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 159 papers.

0numbers the graph read from it
0cells of the map it votes in
159citing papers in PubMed
24.4field-weighted citation impact, top 1% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

159 citing papers in PubMed, 263 citations in OpenAlex.

  1. Trial
  2. Review
  3. Article
  4. Review
  5. Article
  6. Article
  7. Review
  8. Review
  9. Article
  10. Review
  11. Article
  12. Review
  13. Article
  14. Article
  15. Review
  16. Article
  17. Article
  18. Review
  19. Article
  20. Article

99 more citing papers are in PubMed but not listed here.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

18 authors at 5 institutions in 1 country.

William J SullivanDepartment of Biological Chemistry, David Geffen School of Medicine, University of California, Los Angeles (UCLA), Los Angeles, CA 90095, USA; Department of Molecular and Medical Pharmacology, David Geffen School of Medicine, UCLA, Los Angeles, CA 90095, USA.
Peter J MullenDepartment of Biological Chemistry, David Geffen School of Medicine, University of California, Los Angeles (UCLA), Los Angeles, CA 90095, USA.
Ernst W SchmidDepartment of Biological Chemistry, David Geffen School of Medicine, University of California, Los Angeles (UCLA), Los Angeles, CA 90095, USA.
Aimee FloresDepartment of Molecular, Cell, and Developmental Biology, UCLA, Los Angeles, CA 90095, USA; Molecular Biology Institute, UCLA, Los Angeles, CA 90095, USA.
Milica MomcilovicDepartment of Pulmonary and Critical Care Medicine, David Geffen School of Medicine, UCLA, Los Angeles, CA 90095, USA.
Mark S SharpleyDepartment of Molecular, Cell, and Developmental Biology, UCLA, Los Angeles, CA 90095, USA.
David JelinekDepartment of Molecular, Cell, and Developmental Biology, UCLA, Los Angeles, CA 90095, USA.
Andrew E WhiteleyDepartment of Biological Chemistry, David Geffen School of Medicine, University of California, Los Angeles (UCLA), Los Angeles, CA 90095, USA.
Matthew B MaxwellDepartment of Biological Chemistry, David Geffen School of Medicine, University of California, Los Angeles (UCLA), Los Angeles, CA 90095, USA.
Blake R WildeDepartment of Oncological Sciences, Huntsman Cancer Institute, University of Utah, Salt Lake City, UT 84112, USA.
Utpal BanerjeeDepartment of Biological Chemistry, David Geffen School of Medicine, University of California, Los Angeles (UCLA), Los Angeles, CA 90095, USA; Department of Molecular, Cell, and Developmental Biology, UCLA, Los Angeles, CA 90095, USA; Molecular Biology Institute, UCLA, Los Angeles, CA 90095, USA; Eli and Edythe Broad Center of Regenerative Medicine and Stem Cell Research, UCLA, Los Angeles, CA 90095, USA.
Hilary A CollerDepartment of Biological Chemistry, David Geffen School of Medicine, University of California, Los Angeles (UCLA), Los Angeles, CA 90095, USA; Department of Molecular, Cell, and Developmental Biology, UCLA, Los Angeles, CA 90095, USA; Eli and Edythe Broad Center of Regenerative Medicine and Stem Cell Research, UCLA, Los Angeles, CA 90095, USA; Jonsson Comprehensive Cancer Center, UCLA, Los Angeles, CA 90095, USA.
David B ShackelfordDepartment of Pulmonary and Critical Care Medicine, David Geffen School of Medicine, UCLA, Los Angeles, CA 90095, USA; Jonsson Comprehensive Cancer Center, UCLA, Los Angeles, CA 90095, USA.
Daniel BraasDepartment of Molecular and Medical Pharmacology, David Geffen School of Medicine, UCLA, Los Angeles, CA 90095, USA; UCLA Metabolomics Center, Los Angeles, CA 90095, USA.
Donald E AyerDepartment of Oncological Sciences, Huntsman Cancer Institute, University of Utah, Salt Lake City, UT 84112, USA.
Thomas Q de Aguiar VallimDepartment of Biological Chemistry, David Geffen School of Medicine, University of California, Los Angeles (UCLA), Los Angeles, CA 90095, USA; Department of Medicine, David Geffen School of Medicine, UCLA, Los Angeles, CA 90095, USA.
William E LowryDepartment of Molecular, Cell, and Developmental Biology, UCLA, Los Angeles, CA 90095, USA; Molecular Biology Institute, UCLA, Los Angeles, CA 90095, USA; Eli and Edythe Broad Center of Regenerative Medicine and Stem Cell Research, UCLA, Los Angeles, CA 90095, USA; Jonsson Comprehensive Cancer Center, UCLA, Los Angeles, CA 90095, USA.
Heather R ChristofkDepartment of Biological Chemistry, David Geffen School of Medicine, University of California, Los Angeles (UCLA), Los Angeles, CA 90095, USA; Department of Molecular and Medical Pharmacology, David Geffen School of Medicine, UCLA, Los Angeles, CA 90095, USA; Eli and Edythe Broad Center of Regenerative Medicine and Stem Cell Research, UCLA, Los Angeles, CA 90095, USA; Jonsson Comprehensive Cancer Center, UCLA, Los Angeles, CA 90095, USA. Electronic address: hchristofk@mednet.ucla.edu.
University of California, Los Angeles · USBroad Center · USUCLA Jonsson Comprehensive Cancer CenterHuntsman Cancer Institute · USUniversity of Utah · US

Funding

Women's CancersP30CA016042 · NCI · UNIVERSITY OF CALIFORNIA LOS ANGELES · PI Samuel Wheeler French · 1985 to 2026
$134.5M
TUMOR CELL SURFACES AND CHROMOSOMEST32CA009056 · NCI · UNIVERSITY OF CALIFORNIA LOS ANGELES · PI Gay M Crooks, David A. Nathanson · 1985 to 2026
$10.5M
Nutrient Regulation of Cancer Cell GrowthR01CA215185 · NCI · UNIVERSITY OF CALIFORNIA LOS ANGELES · PI Heather Christofk · 2018 to 2026
$4.3M
Metabolic Control of Hair Follicle Stem Cell Homeostasis and TumorigenesisR01AR070245 · NIAMS · UNIVERSITY OF CALIFORNIA LOS ANGELES · PI CHRISTOFK, HEATHER, LOWRY, WILLIAM E · 2018 to 2022
$2.1M
Novel Post-Transcriptional Regulators of Lipid MetabolismR01DK112119 · NIDDK · UNIVERSITY OF CALIFORNIA LOS ANGELES · PI VALLIM, THOMAS A · 2017 to 2020
$1.7M
NCI NIH HHS P30 CA016042NCI NIH HHS R01 CA215185NCI NIH HHS T32 CA009056NIAMS NIH HHS R01 AR070245NIDDK NIH HHS R01 DK112119
6 · The paper itself

Abstract

The metabolic state of a cell is influenced by cell-extrinsic factors, including nutrient availability and growth factor signaling. Here, we present extracellular matrix (ECM) remodeling as another fundamental node of cell-extrinsic metabolic regulation. Unbiased analysis of glycolytic drivers identified the hyaluronan-mediated motility receptor as being among the most highly correlated with glycolysis in cancer. Confirming a mechanistic link between the ECM component hyaluronan and metabolism, treatment of cells and xenografts with hyaluronidase triggers a robust increase in glycolysis. This is largely achieved through rapid receptor tyrosine kinase-mediated induction of the mRNA decay factor ZFP36, which targets TXNIP transcripts for degradation. Because TXNIP promotes internalization of the glucose transporter GLUT1, its acute decline enriches GLUT1 at the plasma membrane. Functionally, induction of glycolysis by hyaluronidase is required for concomitant acceleration of cell migration. This interconnection between ECM remodeling and metabolism is exhibited in dynamic tissue states, including tumorigenesis and embryogenesis.

Indexed as

Carbohydrate MetabolismCarrier ProteinsCell Line, TumorExtracellular MatrixGlucoseGlucose Transporter Type 1GlycolysisHumansHyaluronic AcidHyaluronoglucosaminidaseIntercellular Signaling Peptides and ProteinsSignal TransductionTristetraprolinCarrier ProteinsGlucoseGlucose Transporter Type 1Hyaluronic AcidHyaluronoglucosaminidaseIntercellular Signaling Peptides and ProteinsSLC2A1 protein, humanTristetraprolinTXNIP protein, humanZFP36 protein, humancell biologycell migrationextracellular matrixglucose metabolismGLUT1 traffickinghyaluronidasemRNA degradationreceptor tyrosine kinase signalingTXNIPZFP36

Identifiers

PMID30197082
PMCPMC6151140
OpenAlexW2892257190

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.